Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242339 (dyslipidemia)
 13,927 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Many statistics demonstrate a definite improvement of myocardial infarction during hospitalization, especially a decrease in the mortality. It appears tempting to credit that improvement to the numerous modifications of the treatment of this dangerous disease in the last few decades. The study reported here indicates, however, that other factors must be taken into account. We compared the evolution of two groups of patients hospitalized for acute myocardial infection, 10 years apart: The first group (G1) of 731 patients corresponds to years 1970-1975; the second group (G2) of 729 patients, corresponds to the years 1984-85-86. During these ten years, mortality decreased by 38 p. cent, from 19.2 p. cent (G1) to 11.9 p. cent (G2). This decrease remains significant regardless of age and sex, except in two subgroups with the least number of patients, i.e. women under the age of 65 and men over 65. It should be noted that rhythm disorders occur with the same frequency in both sub-groups while atrio-ventricular blocks seem to have decreased. The difference in the mortality cannot be attributed to the patient's selection. In fact, in both groups, they are comparable regarding the men/women ratio, the age distribution and the presence of main risk factors (tobacco abuse, dyslipidemia, arterial hypertension, diabetes, heredity). The treatment results in many alterations especially concerning diuretics which seem to be used in approximately 30 p. cent of the patients in both groups. On the contrary, steroids, prescribed in 25.3 p. cent of G1 patients are abandoned; electro-systolic stimulation established in 21.2 p. cent of G1 patients, concerned only 4 p. cent of G2 patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Ann Cardiol Angeiol (Paris) 1987 Dec
PMID:[Acute myocardial infarction. Different treatment, different prognosis?]. 332 15

Emotional-painful stress in rats results in the increase of atherogenic and decrease of antiatherogenic lipoprotein fractions. Adaptation of animals to periodic intermittent hypoxia significantly enhanced the proportion of antiatherogenic lipoproteins in the blood and reduced the degree of post-stress dyslipidemia.
Biull Eksp Biol Med 1986 Dec
PMID:[Prevention of stress dyslipidemia by adapting animals to the periodic action of hypoxia]. 380 20

The Authors have analyzed the complex problems of the possible binding between uric acid and plasma proteins using two methods consisting of serum ultrafiltration at 22 degrees C or electrophoresis on different supports with successive specific coloration of the free and bound uric acid. The percentage of free and bound uric acid was established in serum from normal subjects, patients with primary gout, patients with renal insufficiency treated by dialysis and subjects with type IV dyslipidemia. The Authors discuss the results obtained as regards the possible role played by urate-plasma proteins binding in the interpretation of a genetic defect present in gouty patients involving a diminished uric acid binding capacity of plasma proteins.
Quad Sclavo Diagn 1980 Dec
PMID:[Study of the binding between uric acid and plasma proteins (author's transl)]. 745 62

We studied outcome of management of metabolic cardiovascular risk factors in 155 randomly chosen Hispanic hypertensive patients (mean age, 63 +/- 1 years; 79% female) screened for dyslipidemia. Hypertriglyceridemia (n = 12) or high risk-adjusted low-density lipoprotein cholesterol (LDL-C) (n = 89) was found in 65%. Triglycerides did not change (6.16 +/- 0.58 to 7.44 +/- 2.34 mmol/L; P = NS) over 2.2 +/- 0.5 years. Only 58 patients with high LDL-C were treated, and 8 had no follow-up lipid tests. In the other 50, LDL-C decreased by 10 +/- 3% (P < .001) over 2.8 +/- 0.2 years but attained goal in only 12. In a subset of 24 patients with extended follow-up (3.8 +/- 0.2 years), there was an initial marked decline in LDL-C, followed by a rebound to baseline levels. In 29 of 54 patients with normal LDL-C, lipid testing was markedly overused compared with recommendations. Obesity (n = 94, 61%) did not improve in those with repeated data (+0.6 +/- 0.8 kg; P = NS; n = 40) over 2.7 +/- 0.3 years. Forty-four of 63 patients with type II diabetes had repeated measurement of glycosylated hemoglobin, with no change (10.5 +/- 0.5% to 11.2 +/- 0.5%; P = NS) over 2.2 +/- 0.3 years. Ten-year risk of coronary events (Framingham cohort parametric regression) calculated for 61 patients with known untreated blood pressures (169 +/- 3/98 +/- 1 mm Hg) was 21.0 +/- 1.7%, with a skewed distribution reaching high values (66%) and attributable in large part (72%) to modifiable risk factors.(ABSTRACT TRUNCATED AT 250 WORDS)
Hypertension 1995 Dec
PMID:Suboptimal outcome of management of metabolic cardiovascular risk factors in Hispanic patients with essential hypertension. 749 72

The Felodipine Atherosclerosis Prevention Study is designed to evaluate the efficacy of the calcium antagonist felodipine ER and combined felodipine/simvastatin therapy on retarding the progression of atherosclerosis, estimated by serial changes in coronary calcium evaluated by noninvasive electron beam computed tomography. Subjects include 180 men and women aged 40 to 69 and 50 to 69 years, respectively, with moderate type IIa dyslipidemia, with either cardiovascular disease or risk factors. All subjects receive simvastatin lipid-lowering therapy, and are randomized either to felodipine or placebo for a treatment period of 2 years. Monitoring of blood chemistry, measures of lipids and apolipoproteins, blood pressure, evaluation of symptoms, and interim clinical event monitoring are done at routine follow-up visits. Baseline and 2-year follow-up electron beam computed tomography, measuring changes in total calcium score, area, and mass, evaluate the effects of intervention on the progression of calcified atherosclerosis. The results from the Felodipine Atherosclerosis Prevention Study will provide valuable information about the effect of felodipine alone and in combination with simvastatin on progression of calcified atherosclerosis evaluated noninvasively.
Am J Cardiol 1995 Dec 15
PMID:Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: rationale and design of the Felodipine Atherosclerosis Prevention Study (FAPS). 750 3

The Bogalusa Heart Study now establishes that precursors of adult cardiovascular diseases begin in childhood. The clearest evidence comes from autopsy studies that show coronary atherosclerotic lesions occur in early life and are strongly associated with very-low-density lipoprotein cholesterol, systolic and diastolic blood pressure, and obesity, and have an inverse relationship with high-density lipoprotein cholesterol. Observations of cardiovascular risk factors span a period of life from birth to 31 years of age, and longitudinal studies span a 15-year period. Risk factor variables tend to persist over time, "track." Although tracking is best for height and weight, low-density lipoprotein cholesterol and serum total cholesterol track at a high order; blood pressure tends to track at a lower order. Obesity and body fatness have an adverse influence on risk factors in children, just as noted in adults, with central obesity becoming more obvious after puberty, and having a greater adverse effect on risk factors. The emergence of abnormal levels of risk factors by adult criteria begins to occur in young adults, and is not evident in childhood. Retrospective studies, interestingly, for obesity, higher blood pressure, and dyslipidemia reveal evidence of their presence already in childhood. These findings have strong implications for undertaking prevention in early life.
Am J Med Sci 1995 Dec
PMID:Rationale to study the early natural history of heart disease: the Bogalusa Heart Study. 750 19

Serum lipoproteins are important risk factor variables for coronary artery disease (CAD). Studies of a large population of young individuals show changes in lipoproteins in childhood are race- (black-white) and sex-specific and certain changes occur during growth phases. White boys show adverse changes in lipoprotein levels during sexual maturation that mark them at high risk for CAD. Further, low-density lipoprotein particles are relatively apolipoprotein B enriched in white children, especially boys, a characteristic associated with low levels of high-density lipoprotein cholesterol. The impact of apolipoprotein E genotype on serum lipoproteins seen in adults is already apparent in children, which may be helpful in identifying a high-risk group. Observations of child-parent associations in terms of parental myocardial infarction and levels of lipoprotein variables in the offspring suggest that childhood profiles of lipoprotein (a), apolipoprotein A-I, and apolipoprotein B may be helpful as markers of future CAD. Clustering of increased levels of truncal fat, insulin, and blood pressure is often seen in young adults with an adverse lipoprotein profile. This clustering is related to subtle abnormalities in carbohydrate and lipid metabolism and obesity in childhood. The fact that lipoprotein levels persist from childhood to young adulthood underscores the importance of detection and management of dyslipidemia early in life.
Am J Med Sci 1995 Dec
PMID:Childhood lipoprotein profiles and implications for adult coronary artery disease: the Bogalusa Heart Study. 750 26

Patients with dyslipidemia were evaluated with regard to the 5 drugs regimen: simvastatin (average dose, 11.8 mg/day), gemfibrozil (dose 963 mg/day), bezafibrate (433 mg/day), fenofibrate (211 mg/day) and acipimox (667 mg/day). The responses to the drug were divided into different time periods and the magnitude of responses were presented either as average changes in per cent from baseline or as proportion of patients (also in %) whose levels changed by a predetermined percentage. These predetermined percentage took into account the variation observed among patients who had more than 3 measurements during baseline. These levels for significant changes were 16 per cent for total cholesterol (TC), 25-30 per cent for high- and low-density lipoprotein (HDL and LDL), and 44 per cent for triglyceride (TG). Our subjects responded to the drugs within the range reported by other investigators except for acipimox which produced no alteration. Sixty to 100 per cent of patients reduced their TC by 16 per cent with an average change in TC of around -16 per cent to -24 per cent. Simvastatin and fenofibrate appeared most effective in altering TC. The HDL increased 10 per cent to 29 per cent depending on the drug but in terms of proportion that responded by an increment greater than 25 per cent, this was seen in only 23 per cent to 45 per cent of the patients. Long term follow-up which was possible only on 42 patients showed 11 who lessened their response and 6 whose response became more marked.(ABSTRACT TRUNCATED AT 250 WORDS)
J Med Assoc Thai 1993 Dec
PMID:Observation on the short and long term response to anti-lipemic drugs in southern Thailand. 779 16

The insulin resistance syndrome (IRS) is characterized by a constellation of interrelated coronary heart disease (CHD) risk factors, including dyslipidemia, obesity, central obesity, elevated systolic blood pressure, and hyperinsulinemia. Factor analysis was used to investigate the clustering of these risk factors in individuals by examining the correlational structure among these variables. Data from 281 genetically unrelated nondiabetic women who participated in exam 2 (1979 to 1980) of the Kaiser Permanente Women Twins Study were used. Factor analysis reduced 10 correlated risk factors to 3 uncorrelated factors, each reflecting a different aspect of the IRS: factor 1 (increased body weight, waist circumference, fasting insulin, and glucose), factor 2 (increased postload and fasting glucose and insulin and systolic blood pressure), and factor 3 (larger low-density lipoprotein particles, decreased plasma triglycerides, and increased high-density lipoprotein). Together, the factors explained nearly 66% of the total variance in the data. Thus, factor analysis defined three distinct aspects of the IRS in this sample of nondiabetic women. These factors may reflect separate underlying mechanisms of the syndrome, each of which may also be involved in CHD risk.
Arterioscler Thromb 1994 Dec
PMID:Multivariate analysis of the insulin resistance syndrome in women. 798 Nov 83

Efficacy and acceptability of rilmenidine in populations with high cardiovascular risk has been established in short- or mid-term studies (1.5-6 months) enrolling relatively small numbers of patients. The present open study was undertaken to compare, on a larger scale, the efficacy and acceptability of a 12-month rilmenidine treatment in high-risk outpatients versus the results obtained in the general population and to check for unexpected adverse events. A total of 2,635 hypertensive patients (supine diastolic blood pressure [SDBP] > 90 mm Hg) were enrolled, including a high-risk population with 1,591 patients aged > 60 (60.3%), 1,007 patients with dyslipidemia (38.2%), 393 with diabetes (14.9%), 328 with chronic renal failure (12.4%), 301 with angina pectoris (11.4%), and 84 with chronic heart failure (3.2%). All patients were treated by rilmenidine 1 mg/day during the first 6 weeks; then (at 1.5 months), if SDBP was > 90 mm Hg, dosage of rilmenidine was 1 mg twice daily during the following 6 weeks. From month 3 to month 12, any other antihypertensive drugs could be added if SDBP remained > 90 mm Hg. In comparison with the general population, the percentage of high-risk patients whose monotherapy normalized blood pressure (SDBP < or = 90 mm Hg) was slightly lower at month 1.5 (58-66%, according to the risk group, vs 68% in the general population) and month 3 (73-82% vs 85%). At month 12, all treatments taken as a whole (monotherapy and combination therapy) led to the normalization of blood pressure in 94% of patients in the general population and in populations at risk.(ABSTRACT TRUNCATED AT 250 WORDS)
Am J Cardiol 1994 Dec 22
PMID:Long-term control of blood pressure by rilmenidine in high-risk populations. 799 87


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>